Drug information provided by: Merative, Micromedex®
Naxitamab-gqgk injection is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat relapsed (has come back) or refractory (did not respond to previous treatment) high-risk neuroblastoma (a type of cancer that most often occurs in young children) in the bone or bone marrow in patients who have shown a partial response, a minor response, or have stable disease to previous treatment. This medicine is a GD2-binding monoclonal antibody.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?